COMMUNIQUÉS West-GlobeNewswire

Precision Optics Schedules Fourth Quarter and Fiscal Year 2025 Conference Call for September 29, 2025
24/09/2025
GARDNER, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/ [...]
uniQure Announces $200 Million Proposed Public Offering
24/09/2025
LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced [...]
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
24/09/2025
GAITHERSBURG, Md., Sept. 24, 2025 (GLOBE NEWSWIRE) -- In recognition of several observances in September meant to keep the national opioid poisoning epidemic front and center, Emergent BioSolutions Inc. (NYSE: EBS) [...]
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
24/09/2025
IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a plenary [...]
Shareholders of Verona Pharma Approve Proposed Acquisition by Merck
24/09/2025
Transaction expected to close on October 7, 2025 LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory [...]
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
24/09/2025
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten public offering of [...]
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
24/09/2025
NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. [...]
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
24/09/2025
- 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory [...]
CROSSJECT présente ses résultats financiers et les principaux faits marquants pour le premier semestre 2025
24/09/2025
Communiqué de presse CROSSJECT présente ses résultats financiers et les principaux faits marquants pour le premier semestre 2025 Position de trésorerie : 6.3 millions d'euros, contre 7,0 millions d’euros au 31 décembre [...]
CROSSJECT presents its financial results and key highlights for the first half of 2025
24/09/2025
Press release CROSSJECT presents its financial results and key highlights for the first half of 2025 Cash position: €6.3 million, compared to €7.0 million as of December 31 2024, demonstrating the Company's excellent [...]
Inventiva to Host Analyst and Investor Event on October 8, 2025
24/09/2025
Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026 Three renowned international experts and a patient representative [...]
Inventiva organise un événement analystes et investisseurs le 8 octobre 2025
24/09/2025
Le programme inclura une mise à jour sur son médicament candidat, lanifibranor, en amont des résultats principaux de l’étude de Phase 3 NATiV3 attendus au second semestre 2026 Trois experts internationaux de renom et un [...]
SoCalBio Investor & Partnership Conference to Feature Keynotes from SetPoint CEO Murthy Simhambhatla, PhD, and MedTech Industry Deal-Maker Ray Cohen
24/09/2025
Breakthrough Therapies and Life Sciences Leadership Take Center Stage October 1–2 in Newport Beach LOS ANGELES, Sept. 24, 2025 (GLOBE NEWSWIRE) -- The Southern California Biomedical Council (SoCalBio) today announced [...]
New Report Offers Recommendations to Advance Brain Capital for Economic and Workforce Growth
24/09/2025
The Business Collaborative for Brain Health calls on global leaders to invest in workforce brain capital NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- The Business Collaborative for Brain Health (BCBH), led by [...]
Unity Consortium Announces Bold Commitment to Empower Teen Vaccine Ambassadors at Clinton Global Initiative Meeting
24/09/2025
Launch of Trusted Teen CommUNITY Program to Reach 12 Million Annually NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Unity Consortium today announced the launch of its new Trusted Teen CommUNITY program. This ambitious [...]
Guerbet : H1 2025 results : H1 revenue: €387.8 million, down 5.4% at CER and on a like-for-like basis, mainly due to the decline in activity in France
24/09/2025
H1 2025 results Activity and profitability H1 revenue: €387.8 million, down 5.4% at CER 1 and on a like-for-like basis 2 , mainly due to the decline in activity in France Restated EBITDA margin 3 came out at 12.9%, [...]
Guerbet : Résultats semestriels 2025 : Chiffre d’affaires du 1er semestre : 387,8 M€, en retrait de 5,4% à TCC et périmètre comparable principalement en lien avec la baisse d’activité en France
24/09/2025
Résultats semestriels 2025 Activité et rentabilité Chiffre d’affaires du 1 er semestre : 387,8 M€, en retrait de 5,4% à TCC 1 et périmètre comparable 2 , principalement en lien avec la baisse d’activité en France La [...]
Eurobio Scientific : résultat du 1er semestre 2025
24/09/2025
RESULTAT DU 1 ER SEMESTRE 2025 Chiffre d’affaires en croissance de 10% à 80,7 M€ les produits propriétaires atteignent 36% du CA la part du CA hors France est de 42% Résultats 2025 impacté par le transfert de la [...]
EUROBIO SCIENTIFIC: RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025
24/09/2025
RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025 Revenue up 10% to €80.7 million Proprietary products account for 36% of revenue 42% of revenue generated outside France 2025 results impacted by the transfer of [...]

Pages